Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data

J Infect Dis. 2000 Jan;181(1):406. doi: 10.1086/315199.
No abstract available

Publication types

  • Clinical Trial
  • Comment
  • Letter

MeSH terms

  • AIDS Vaccines / immunology
  • AIDS Vaccines / therapeutic use*
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Follow-Up Studies
  • Gene Products, env / genetics
  • Gene Products, env / immunology
  • Gene Products, env / therapeutic use
  • Gene Products, rev / genetics
  • Gene Products, rev / immunology
  • Gene Products, rev / therapeutic use
  • HIV Infections / drug therapy*
  • HIV-1*
  • Humans
  • Vaccination*
  • Vaccines, DNA / immunology
  • Vaccines, DNA / therapeutic use*
  • rev Gene Products, Human Immunodeficiency Virus

Substances

  • AIDS Vaccines
  • Gene Products, env
  • Gene Products, rev
  • Vaccines, DNA
  • rev Gene Products, Human Immunodeficiency Virus